SAVA - Above MA's Possible 15% Target

2019년 9월 17일

Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

SHORT INTEREST
1.64M 08/30/19

P/E Current
-2.07

P/E Ratio (with extraordinary items)
-5.00

Average Recommendation: BUY

Average Target Price: 3.00